Bain Capital, an investment firm, completed a $300m investment in Cardurion Pharmaceuticals, a cardiovascular biotechnology company. “We could not be more excited to welcome Bain Capital as investors in this transformational milestone for Cardurion. We have a shared vision to continue to build a world-class cardiovascular company pursuing treatments for a broad range of debilitating diseases. This funding will allow us to advance our first-in-class PDE9 inhibitor into a major Phase 2 trial in heart failure and to support the initiation of first-in-human studies with our CaMKII inhibitor program in several cardiovascular indications. We look forward to leveraging the experience and resources of our investors to build and scale Cardurion as a leading cardiovascular biotechnology company," Peter Lawrence, Cardurion CEO.